Impact BioMedical Approves Reverse Stock Split Ahead of Zoar Ltd. Merger

Impact BioMedical Inc. (IBO) announced a 1-for-12.62 reverse stock split of its common stock, effective September 23, 2026. This action is intended to facilitate its merger with Zoar Ltd. Following the merger, Impact stockholders will receive one share of Zoar Ltd. for every four post-split Impact shares.